295 results about "Low blood sugar level" patented technology

Apparatuses and methods for medical monitoring physiological characteristic values such as blood glucose levels for the treatment of diabetes, are presented. The apparatuses and methods provide for preventing any negative consequence in the operation of a monitor and / or infusion device as a result of disorientation that may occur from waking from slumber with a low blood glucose level. In addition, a graphical display is disclosed incorporating a variety of enhancements which readily conveys to the user historical as well as real time information regarding the measured characteristic value.

Described herein are methods, devices, and microprocessors useful for predicting a hypoglycemic event in a subject. The hypoglycemic predictive approach described herein utilizes information obtained from a data stream, e.g., frequently obtained glucose values (current and / or predicted), body temperature, and / or skin conductance, to predict incipient hypoglycemic events and to alert the user.

A method, system, and computer program product related to the maintenance of optimal control of diabetes, and is directed to predicting patterns of hypoglycemia, hyperglycemia, increased glucose variability, and insufficient or excessive testing for the upcoming period of time, based on blood glucose readings collected by a self-monitoring blood glucose device. The method, system, and computer program product pertain directly to the enhancement of existing home blood glucose monitoring devices, by introducing an intelligent data interpretation component capable of predicting and alerting the user to periods of increased risk for hyperglycemia, hypoglycemia, increased glucose variability, and ineffective testing, and to the enhancement of emerging self-monitoring blood glucose devices by the same features. With these predictions the diabetic can take steps to prevent the adverse consequences associated with hyperglycemia, hypoglycemia, and increased glucose variability.

A method, system, and computer program product related to the diagnosis of diabetes, and is directed to predicting the long-term risk of hyperglycemia, and the long-term and short-term risks of severe hypoglycemia in diabetics, based on blood glucose readings collected by a self-monitoring blood glucose device. The method, system, and computer program product pertain directly to the enhancement of existing home blood glucose monitoring devices, by introducing an intelligent data interpretation component capable of predicting both HbA1c and periods of increased risk of hypoglycemia, and to the enhancement of emerging continuous monitoring devices by the same features. With these predictions the diabetic can take steps to prevent the adverse consequences associated with hyperglycemia and hypoglycemia.

A diabetes management system or process is provided herein that may be used to analyze and recognize patterns for a large number of blood glucose concentration measurements and other physiological parameters related to the glycemia of a patient. In particular, a method of monitoring glycemia in a patient may include storing a patient's data on a suitable device, such as, for example, a blood glucose meter. The patient's data may include blood glucose concentration measurements. The diabetes management system or process may be installed on, but is not limited to, a personal computer, an insulin pen, an insulin pump, or a glucose meter. The diabetes management system or process may identify a plurality of pattern types from the data including a testing / dosing pattern, a hypoglycemic pattern, a hyperglycemic pattern, a blood glucose variability pattern, and a comparative pattern. After identifying a particular pattern with the data management system or process, a warning message may be displayed on a screen of a personal computer or a glucose meter. Other messages can also be provided to ensure compliance of any prescribed diabetes regiments or to guide the patient in managing the patient's diabetes.

Methods related to the treatment of diabetes and improving the control of blood glucose levels are provided. In particular, methods are provided for effectively reducing postprandial glucose excursions while reducing the incidence of clinically significant late postprandial hypoglycemia by administered an insulin composition in a form suitable for pulmonary administration. Additionally, methods for effectively reducing post-prandial glucose excursions while reducing the incidence of clinically significant late postprandial hypoglycemia by administered an insulin composition in a form suitable for pulmonary administration along with a long-acting basal insulin.

A system, computer program product, method and algorithm for evaluation of blood glucose variability—one of the most important parameters of diabetes management. An embodiment of the method may use routine self-monitoring blood glucose (SMBG) data collected over a period of 2-6 weeks, for example, based on a theory of risk analysis of blood glucose data. One aspect may include a method, system and computer program product for computing the Average Daily Risk Range (ADRR)—a measure of overall glucose variability. Another aspect may include a method, system, and computer program product for estimating separately the glucose variability in the hypoglycemic range via a Low BG Index (LBGI) and the glucose variability in the high BG range via High BG Index (HBGI) followed by a combination of the two indices into a single variability display.

An Adaptive Advisory Control (AA Control) interactive process involving algorithm-based assessment and communication of physiologic and behavioral parameters and patterns assists patients with diabetes with the optimization of their glycemic control. The method and system may uses all available sources of information about the patient; (i) EO Data (e.g. self-monitoring of blood glucose (SMBG) and CMG), (ii) Insulin Data (e.g. insulin pump log files or patient treatment records), and (iii) Patient Self Reporting Data (e.g. self treatment behaviors, meals, and exercise) to: retroactively assess the risk of hypoglycemia, retroactively assess risk-based reduction of insulin delivery, and then report to the patient how a risk-based insulin reduction system would have acted consistently to prevent hypoglycemia.

A biocompatible insulin delivery device is provided comprising an insulin reservoir sealed with a glucose-responsive plug or membrane. The plug functions to release insulin from the reservoir in response to a hyperglycemic glucose concentration and to prevent insulin release from the reservoir in response to hypoglycemic glucose concentration. In one embodiment, the plug is made of a biocompatible polymeric matrix comprising an inorganic component, a stimulus-responsive component and a catalytic component.

A method, system, and computer program product related to the detection of physical activity using changes in heart rate. The method, system, and computer program product evaluates short term glucose demand and long term insulin action due to physical activity. The method, system, and computer program product is further related to the improvement of open and closed loop control of diabetes by accounting for the metabolic changes due to physical activity. The method, system, and computer program product is directed to detecting in real time the short and long term effects of physical activity on insulin action via heart rate analysis, and recommending changes in insulin dosing to compensate for the effects of physical activity. With these recommendations, the open and closed loop control of diabetes can be improved and steps can be taken to prevent hypoglycemia that may result from increased insulin sensitivity due to physical activity.

In an implantable medical device for monitoring glucose concentration in the blood, a blood-glucose concentration analysis is performed using correlations of blood-glucose concentration with measures of metabolic oxygen consumption including oxymetric, and / or temperature. Analysis of electrocardiographic data is used in a parallel method to detect and / or confirm the onset and / or existence and / or extent of hypoglycemia and / or hyperglycemia. Blood-glucose concentration calculation is enhanced by using the combination of the oxygen metabolism analysis and electrocardiographic analysis.

A combined rapid acting-long acting insulin formulation has been developed in which the pH of the rapid acting insulin is adjusted so that the long acting glargine remains soluble when they are mixed together. In the preferred embodiment, this injectable basal bolus insulin is administered before breakfast, provides adequate bolus insulin levels to cover the meal, does not produce hypoglycemia after the meal and provides adequate basal insulin for 24 hours. Lunch and dinner can be covered by two bolus injections of a fast acting, or a rapid acting or a very rapid acting insulin. As a result, a patient using intensive insulin therapy should only inject three, rather than four, times a day.

In one embodiment, the present invention is directed to a communication device that analyzes received utterances and detects when the speaker has a target physical condition.

The invention discloses a natural food additive which belongs to the technical field of food additives. The natural food additive is characterized by comprising the following substances in percentage by weight: 20%-30% of a red bayberry anthocyanin extractive, 10%-20% of a purple sweet potato anthocyanin extractive, 10%-40% of a mulberry anthocyanin extractive, 10%-50% of an okra pectin and polysaccharide extractive, 10%-20% of a folium ginkgo extractive, 0.0005%-0.0008% of selenium yeast, 2%-10% of seaweed meal, and 5%-10% of ganoderma lucidum spore powder. The natural food additive has strong functions of oxidation resistance, aging resistance, fatigue resistance, invigorating the kidney, strengthening Yang, improving immunity and reducing blood sugar, cholesterol and triglyceride. After the natural food additive is detected, the total anthocyanin content is 15%-36%, the total flavone content is 16%-28% and the total phenolic acid content is 18%-29%.

Methods for treating impaired glucose tolerance and early and late stage diabetes in mammals, for prophylactically sparing β-cell function, aiding in preventing β-cell death, preventing the onset of overt diabetes in a mammal with type 2 diabetes, treating the current level of glycemic control dysfunction of a mammal with impaired glucose tolerance or diabetes, comprising orally administering insulin and a delivery agent that facilitates insulin absorption from the gastrointestinal tract at the time of or shortly before mealtime, e.g., within about 10 minutes prior to ingestion of a meal, on a chronic basis. The methods also comprise, in addition to administering a rapid-acting insulin to provide a first insulin peak, administering a slow acting insulin to provide a second insulin peak occurring at a later time but of a longer duration. These methods achieve improved glycemic control without the risks of hypoglycemia, hyperinsulinemia and weight gain and the need for frequent blood glucose monitoring that are normally associated with insulin therapy.

Methods are disclosed for treating a patient with Type 2 diabetes to decrease hypoglycemic episodes and / or to diminish fluctuations in blood glucose outside of the normal range, comprising administering to said patient, in a therapeutically-effective amount, a food composition that includes a slowly absorbed complex carbohydrate such as uncooked cornstarch. Further disclosed is a method of suppressing appetite in a patient with Type 2 diabetes comprising administering to the subject, in an effective appetite suppressing amount, a food composition that includes a slowly absorbed complex carbohydrate such as uncooked cornstarch. In preferred embodiments, the food composition is in the form of a bar.

The invention discloses a konjac and moringa oleifera noodle and a processing technique thereof. The konjac and moringa oleifera noodle comprises, by mass, 90-120 parts of flour, 0.1-0.2 part of alkali, 1-2 parts of moringa oleifera powder, 1-3 parts of salt, 1-5 parts of konjac powder and 35-50 parts of water. The processing technique of the konjac and moringa oleifera noodle comprises the steps of material preparation, dough kneading, dough curing, continuous rolling, slicing, drying, slicing, metering and packaging. The konjac and moringa oleifera noodle made with the method is good in surface effect, smooth, bright in color and lustre and free of odor, breakage and twisting are avoided after the noodle is placed in water, the noodle is not sticky to teeth after being eaten, capable of being bitten repeatedly, high in elasticity, good in taste and not spicy, and has the faint scent of konjac and freshness of moringa oleifera. Compared with traditional noodles, the konjac and moringa oleifera noodle has the advantages that the noodle has comprehensive nutrients, and can prevent obesity, reduce blood glucose and blood fat, boost immunity and prevent osteoporosis after being eaten for a long time, and the health-care function is remarkable.

A composition is provided which contains policosanol and chromium and / or chromium salts and which may be used for treating, preventing and or reducing metabolic syndrome, hypercholesterolemia and hypoglycemia related diseases, total cholesterol, LDL-cholesterol, LDL / HDL ratio, triglycerides, coronary heart disease (heart attacks and strokes), inflammation, deep-vein thrombosis, immunoregulatory diseases, cardiovascular diseases, obesity, insulin resistance, dyslipidemia, raised blood pressure, fatigue, premenstrual syndrome, anxiety, depression and / or neurodegenerative disorders, and / or raising HDL cholesterol and / or lean body mass in humans and animals. The method comprises administering policosanol and chromium and / or chromium salts which together effectively lower blood glucose levels and lower the LDL / HDL cholesterol ratio. Typically, the administered composition includes about 0.1-10:1 parts by weight of policosanol to chromium and / or chromium salts.

A method of controlling an insulin infusion device involves controlling the device to operate in an automatic basal insulin delivery mode, obtaining a blood glucose measurement for the user, and initiating a correction bolus procedure when: the measurement exceeds a correction bolus threshold value; and a maximum basal insulin infusion rate is reached during the automatic basal insulin delivery mode. The correction bolus procedure calculates an initial correction bolus amount, and scales the initial amount to obtain a final correction bolus amount, such that a predicted future blood glucose level resulting from simulated delivery of the final correction bolus amount exceeds a low blood glucose threshold level. The final amount is delivered to the user during operation in the automatic basal insulin delivery mode.

A method, system and related computer program product for tracking the probability of hypoglycemia from routine self-monitoring of blood glucose (SMBG) data in patients with diabetes. A specific bivariate probability distribution of low BG events based jointly on the Low BG Index (LBGI) and the Average Daily Risk Range (ADRR) is used to predict hypoglycemia probability of occurrence from inputted SMBG data. The SMBG data is retrieved from a series of SMBG data of a patient available from the patient's glucose meter and allows tracking of the probability for future hypoglycemia over a predetermined duration, e.g., a 24 or 48 hour period. The tracking includes presentation of visual and / or numerical output, as we construction of hypoglycemia risk trajectories that would enable warning messages for crossing of predefined thresholds, such as 50% likelihood for upcoming hypoglycemia below 50 mg / dl.

The present invention provides for a computer system that includes at least one server having software stored on a non-transient computer readable medium; where, upon execution of the software, the at least one server is at least configured to: i) receiving, in real-time, an input from a user; ii) receiving, in real-time, physiological data representative of a physiological measurement of physiological characteristic of the user; iii) comparing, in real-time, the physiological measurement of the user to a pre-de-termined physiological value associated with the physiological characteristic retrieved from a database; iv) based on the comparing, determining, in real-time, that a difference between the physiological measurement of the user and the pre-determined physiological value is higher or smaller than the predetermined threshold value, and then: v) generating, in real-time, at least one alert; vi) transmitting, in real-time, the at least one alert.

A method, system, and computer program product related to the maintenance of optimal control of diabetes, and is directed to predicting patterns of hypoglycemia, hyperglycemia, increased glucose variability, and insufficient or excessive testing for the upcoming period of time, based on blood glucose readings collected by a self-monitoring blood glucose device. The method, system, and computer program product pertain directly to the enhancement of existing home blood glucose monitoring devices, by introducing an intelligent data interpretation component capable of predicting and alerting the user to periods of increased risk for hyperglycemia, hypoglycemia, increased glucose variability, and ineffective testing, and to the enhancement of emerging self-monitoring blood glucose devices by the same features. With these predictions the diabetic can take steps to prevent the adverse consequences associated with hyperglycemia, hypoglycemia, and increased glucose variability.

Methods are provided for administering an extended half-life GLP-1 / GIP coagonist peptide to a patient in need thereof for reducing weight gain, inducing weight loss, treating hyperglycemia, reducing blood glucose levels, or normalizing blood glucose levels in said patient.

The invention belongs to the field of health care foods and specifically relates to compound dendrobium candidum and American ginseng buccal tablets and a preparation method thereof. The method comprises the following steps of: performing ultrafine grinding on dendrobium candidum and American ginseng, taking ultrafine powder of the dendrobium candidum and the American ginseng as raw material, adding resistant starch, a sweetening agent and a bonding agent, preparing wet particles, drying, sizing, finally mixing with a lubricating agent, and then tabletting to get finished products. According to the compound dendrobium candidum and American ginseng buccal tablets prepared by the method disclosed by the invention, the raw material is subject to the ultrafine grinding, various biological active substances in the raw material can be retained to the greatest extent, the biological availability is high, and the dendrobium candidum and the American ginseng are compatible for use, so that the effects of resisting fatigue, nourishing Yin, producing body fluid and the like can be enhanced. The resistant starch is added in the buccal tablets so as to enhance the effects of preventing and treating intestinal diseases, reducing blood sugar and the like; and the compound dendrobium candidum and American ginseng buccal tablets are suitable for more people and more suitable for patients with diabetes for taking, have the characteristics of convenience in carrying, convenience in taking, easiness in control of dosage and the like, and are further in line with simple, convenient and fast consumer demands of modern people.

The invention relates to a drug for reducing blood glucose, regulating blood lipid and treating diabetes mellitus combined with hyperlipidemia and other chronic vascular complications and a preparation method thereof. The drug is total alkaloids which are extracted from traditional Chinese medicine golden thread. The preparation method of the drug comprises the following steps: 1) the golden thread herbal medicine is crushed into coarse powder; 2) 5-10 times of the amount of 60-80 percent ethanol is used for carrying out the reflux extraction of the golden thread coarse powder for 1-3 times by 1-2h / time, the filtration is carried out by times, and filtrates are merged. Golden thread extract is obtained by pressure reduction concentration and drying; 3) the golden thread extract is added in 5 times of the amount of 0.5 percent sulfuric acid for dissolution and filtration, the filtrates are respectively regulated to pH9 by lime milk, filtrated and respectively regulated to pH1-2 by hydrochloric acid, sodium chloride is added to allow the salt content to be 10 percent, and the total alkaloids of the golden thread are obtained by even shaking and still placement. Or the golden thread extract is used for separating and purifying the total alkaloids of the golden thread by macroporous resin method. The drying is carried out, and the total alkaloids of the golden thread are prepared into oral formulation or injection formulation. The drug has prominent efficacy for the diabetes mellitus combined with hyperlipidemia and other chronic vascular complications.

The invention discloses a dynamic blood glucose monitor capable of conducting direct monitoring through a mobile phone APP and a control method of the dynamic blood glucose monitor, and relates to wearable equipment used in the field of medical detection and a control method of the wearable equipment. The dynamic blood glucose monitor comprises a wearable blood glucose transmitter, a mobile phoneAPP terminal and a cloud memory which is connected via the mobile phone APP terminal; the blood glucose transmitter is constituted by connecting a blood glucose sensor component and a transmitter component; the mobile phone APP terminal is connected to the blood glucose transmitter via a Bluetooth mode; the mobile phone APP terminal is connected to the cloud memory via a mobile communication network; by pushing blood glucose monitoring data to an authorized user, network sharing of the blood glucose monitoring data is achieved; sports and sleep information of a wearer can be acquired via a three-axis acceleration sensor while continuously acquiring and recording human body blood glucose; recognition and awakening self-rescuing of hypoglycemic coma are offered; the blood glucose monitoringdata is transmitted to intelligent hand-held equipment or other external receiving terminals having wireless transmitting and receiving functions in a wireless transmitting mode; and data display andanalysis as well as far-end alarming and help-seeking services are offered.

The invention relates to a diet extender capable of restraining a diabetic's blood sugar level from rising after a meal. The diet extender comprises the following components by the weight percentage: 8-97 wt percent of indigestion carbohydrate, 1-10 wt percent of food gum, 1-90 wt percent of saccharide with low blood sugar level generation index, and 1-80 wt percent of flavoring agent. The diet extender capable of restraining the diabetic's blood sugar level from rising after the meal adopts water-soluble dietary fibers and the saccharide with the low blood sugar level generation index as raw materials, and ensures that the metabolism of the diet extender doest not depend on insulin, satiety cannot be increased excessively, normal diet cannot be affected, a diabetic can change a food habit of eating frequently but small meals, and enough energy and microelement are obtained from foods on the basis that the blood sugar level is restrained from rising.

The invention relates to a pharmaceutical composition having alpha-glucosidase inhibition activity, wherein the pharmaceutical composition comprises a flavone compound and an alpha-glucosidase inhibitor, the flavone compound is at least one selected from a monomer such as baicalein, quercetin, luteolin, baicalein-7-O-glucoside and catechin, an organic salt of the monomer, and an inorganic salt of the monomer, and the alpha-glucosidase inhibitor is at least one selected from a monomer such as acarbose, voglibose and miglitol, an organic salt of the monomer, and an inorganic salt of the monomer. According to the present invention, the pharmaceutical composition can effectively reduce postprandial blood glucose, can inhibit the activity of alpha-glucosidase adopting starch, maltose and sucrose as substrates, and less uses the alpha-glucosidase inhibitor, such that the efficacy can be improved, the side effect of the alpha-glucosidase inhibitor can be effectively reduced, and hypoglycemia and other problems easily caused by drug combination are effectively solved.

The present invention provides a novel biosensor and measuring method. The novel biosensor of the present invention comprises an electrode having a nanopore structured and catalytically active cyclodextrin attached thereto. The biosensor of the present invention has demonstrated robust analytical performance for direct glucose measurement without mediators or without using native enzyme, which is especially beneficial in the hypoglycemia range.